Harpoon Therapeutics (HARP) Rating Reiterated by Svb Leerink

Share on StockTwits

Svb Leerink reissued their outperform rating on shares of Harpoon Therapeutics (NASDAQ:HARP) in a report released on Tuesday morning. Svb Leerink also issued estimates for Harpoon Therapeutics’ Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($3.77) EPS, Q1 2019 earnings at ($0.36) EPS, Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($1.58) EPS, FY2020 earnings at ($1.67) EPS, FY2021 earnings at ($1.71) EPS, FY2022 earnings at ($2.20) EPS and FY2023 earnings at ($2.76) EPS.

Several other research firms also recently commented on HARP. Canaccord Genuity started coverage on shares of Harpoon Therapeutics in a report on Tuesday. They set a buy rating and a $24.00 price objective on the stock. Wedbush started coverage on shares of Harpoon Therapeutics in a report on Tuesday. They set an outperform rating and a $23.00 price objective on the stock.

NASDAQ HARP opened at $15.55 on Tuesday. Harpoon Therapeutics has a 52 week low of $13.25 and a 52 week high of $17.85.

In other news, major shareholder Bioscience Plc Arix purchased 428,571 shares of the stock in a transaction dated Tuesday, February 12th. The shares were purchased at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Luke Evnin bought 250,000 shares of the stock in a transaction that occurred on Tuesday, February 12th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $3,500,000.00. The disclosure for this purchase can be found here.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer.

Recommended Story: What is the S&P 500 Index?

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply